APA (7th ed.) Citation

P, G., O, B., M, B., JP, C., E, d. B. C., AM, D., . . . MA, F. (2025). Aficamten vs Metoprolol for Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCM Rationale, Study Design, and Baseline Characteristics. JACC. Heart failure, 13(2), 346. https://doi.org/10.1016/j.jchf.2024.11.011

Chicago Style (17th ed.) Citation

P, Garcia-Pavia, et al. "Aficamten Vs Metoprolol for Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCM Rationale, Study Design, And Baseline Characteristics." JACC. Heart Failure 13, no. 2 (2025): 346. https://doi.org/10.1016/j.jchf.2024.11.011.

MLA (9th ed.) Citation

P, Garcia-Pavia, et al. "Aficamten Vs Metoprolol for Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCM Rationale, Study Design, And Baseline Characteristics." JACC. Heart Failure, vol. 13, no. 2, 2025, p. 346, https://doi.org/10.1016/j.jchf.2024.11.011.